Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials
Clinical Endocrinology · 2026-10 · 105 (4) · 452-463
DOI: 10.1111/cen.70166 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Endocrinology, online erschienen am 01.06.2026. Verfasst von John Newell-Price und 6 weiteren Autor:innen. Beteiligte Einrichtung: The School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Quality of Life, Pituitary ACTH Hypersecretion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
Evaluate the effects of osilodrostat short‐ and long‐term treatment on health‐related quality of life (HRQoL) in Cushing's disease.
Design
LINC 3 and LINC 4 studies (pooled analysis). Patients 185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI‐II], 15.6; EuroQol Five Dimensions Five Levels [EQ‐5D‐5L], 0.7).
Measurements
Changes from baseline in CushingQoL, BDI‐II and EQ‐5D‐5L scores. CushingQoL and EuroQol Five Dimensions Three Levels (EQ‐5D‐3L) scores were assessed in analyses of hypocortisolism‐related adverse events (HAEs).
Results
Mean CushingQoL score improved (all p < 0.001) by +7.72 (Week [W]12), +11.45 (W26; achieving minimal clinically important difference [MCID]) and +15.32 (W72). Mean BDI‐II score improved (all p < 0.001) by −19.0% (W12; achieving MCID) and −41.2% (W72). EQ‐5D‐5L utility score improved over W26–72 ( p < 0.01), reaching the MCID range at W26. All items/domains in the HRQoL questionnaires significantly improved over time ( p < 0.001; ordinal mixed‐effects regression), except one BDI‐II item (past failure) and one EQ‐5D‐5L domain (self‐care). CushingQoL total score improved in patients with mild (mean urinary free cortisol [mUFC] ≤ 2x upper limit of normal [ULN]), moderate (mUFC > 2–5 × ULN) and severe (mUFC > 5 × ULN) hypercortisolism. BDI‐II and EQ‐5D‐5L total scores improved in patients with moderate and severe hypercortisolism. Grade 3 HAEs temporarily reduced CushingQoL and EQ‐5D‐3L scores during event weeks. In the multivariable models, longer treatment duration was associated with CushingQoL improvements; higher mUFC, higher body mass index, and occurrence of HAEs were associated with lower CushingQoL scores.
Conclusions
Osilodrostat improved HRQoL, with clinically meaningful, consistent improvements across HRQoL assessments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
- Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
- Recordati Rare Diseases, Puteaux, France.
- MAHTA Intl Sp. z. o. o., Warsaw, Poland.
- Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Beatrice Gueron
Zitieren
APA
Newell-Price, J., Biller, B. M. K., Fleseriu, M., Gueron, B., Binowski, G., Paćkowska, A., & Gadelha, M. R. (2026). Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials. Clinical Endocrinology, 105(4), 452-463. https://doi.org/10.1111/cen.70166
Vancouver
Newell-Price J, Biller BMK, Fleseriu M, Gueron B, Binowski G, Paćkowska A, et al. Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials. Clinical Endocrinology. 2026;105(4):452-463. doi:10.1111/cen.70166
BibTeX
@article{NewellPrice2026,
author = {Newell-Price, John and Biller, Beverly M K and Fleseriu, Maria and Gueron, Beatrice and Binowski, Grzegorz and Paćkowska, Anna and Gadelha, Mônica R},
title = {Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials},
journal = {Clinical Endocrinology},
year = {2026},
volume = {105},
number = {4},
pages = {452--463},
doi = {10.1111/cen.70166}
}
EUVIMED